Going Green in 2019

Register Now

The mission of the Dermatology Summit is to build a community of people who are excited about innovation in dermatology.

This conference uniquely brings together members of the financial community and business leaders from established and emerging companies in the dermatology space to help foster investment and partnerships in the next generation of dermatology companies and products.



Angela M. Christiano, PhD, is the Richard and Mildred Rhodebeck Professor of Dermatology and Professor of Genetics and Development at Columbia University Medical Center. She is also the Director of Basic Science Research in the Department of Dermatology at CUMC. For the past 20 years, Dr. Christiano's research has focused on understanding the molecular processes that lead to inherited skin and hair disorders in humans. Her research career began with the discovery of genetic mutations associated with epidermolysis bullosa, a skin disease that causes severe blistering. Dr. Christiano's recent work has focused on the investigation of the underlying genetic causes of and identification of potential therapies for alopecia areata, an autoimmune form of hair loss. She has published more than 300 papers in peer-reviewed journals and has trained more than 50 postdoctoral researchers and clinical fellows at Columbia University through the Program in Genetics & Development, the Institute of Human Nutrition, the Integrated Program in Cellular, Molecular and Biomedical Studies in the Graduate School of Arts & Sciences, the Clinical and Translational Science Award Program, the Stem Cell Training Program.

Dr. Christiano has received numerous awards, including the New York City Mayor's Award for Excellence in Science and Technology – Young Investigator's Award, Columbia University's Harold and Golden Lamport Research Award for Excellence in Clinical Sciences, the CERIES Research Award, and the North American Hair Research Society's award for Outstanding Paper of the Year, the Montagna Award from the Society for Investigative Dermatology, and the Ebling Award from the European Hair Research Society. Dr. Christiano is a prolific inventor and serial entrepreneur, having filed numerous patents on her discoveries, and successfully moved technologies from the academic setting into the commercial sector. She has co-founded several companies in the dermatology space, including Skinetics Bioscience (RNAi-based dermatology therapeutics, acquired by Sirna Therapeutics, which was acquired by Merck & Co. in 2007), Vixen Pharmaceuticals (JAK inhibitors for treatment of hair disorders, acquired by Aclaris Therapeutics in 2016), and Rapunzel Bioscience, focused on regenerative therapies and stem cell approaches for skin and hair disorders.

Dr. Christiano is currently President of the Society for Investigative Dermatology, and serves as Deputy Editor of the Journal of Investigative Dermatology. She earned her MS and PhD degrees in Microbiology and Molecular Genetics from Rutgers University.

During his 17-year tenure, Allergan Inc. was transformed from a small eye care business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014. Mr. Pyott was recognized by Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014 (ranked #4).

Allergan had been the fastest growing global ophthalmic company for many years and is globally #1 or #2 in multiple specialty areas, including: ophthalmics, medical aesthetics, medical dermatology, neurology, and urologics. The company’s strategy was based on customer focus, investment in R&D, creation of new markets and commercial prioritization of high growth products. As an innovator with a strong background in consumer marketing, Dr. Pyott recognized the potential of BOTOX® to be used for cosmetic and therapeutic purposes. Allergan’s investment in Research & Development increased from less than $100 million in 1998 to over $1 billion in 2014, with the company creating an industry-leading Research & Development pipeline.

Allergan had been the fastest growing global ophthalmic company for many years and is globally #1 or #2 in multiple specialty areas, including: ophthalmics, medical aesthetics, medical dermatology, neurology, and urologics. The company’s strategy was based on customer focus, investment in R&D, creation of new markets and commercial prioritization of high growth products. As an innovator with a strong background in consumer marketing, Dr. Pyott recognized the potential of BOTOX® to be used for cosmetic and therapeutic purposes. Allergan’s investment in Research & Development increased from less than $100 million in 1998 to over $1 billion in 2014, with the company creating an industry-leading Research & Development pipeline.

Before Allergan, Dr. Pyott served as Head of the Novartis Nutrition Division and as a member of the Executive Committee of the Switzerland-based Novartis AG, having worked 17 years in Switzerland, Austria, Spain, Malaysia and the United States.

Dr. Pyott holds a Diploma in International and European Law from the Europa Institute at the University of Amsterdam, a Master of Arts degree from the University of Edinburgh and a Master of Business Administration degree from the London Business School.

Dr. Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation, a member of the Board of Alnylam Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., a member of the Supervisory Board of Royal Philips in the Netherlands and Chairman of privately held Bioniz Therapeutics and a Director of Rani Therapeutics. He chairs an Advisory Board for Commercial Access for Gilead. He is a member of the Governing Board of the London Business School, President of the International Council of Ophthalmology Foundation and is on the Advisory Board of the Foundation of the American Academy of Ophthalmology. He formerly served on the Board, on the Executive Committee and as Board Secretary of the Biotechnology Industry Organization as well as on the Board of Edwards Lifesciences Corporation.

George D. Yancopoulos, MD, PhD, became the Scientific Founder and Chief Scientific Officer of Regeneron in 1989, alongside Founder and Chief Executive Office, Leonard Schleifer, MD, PhD. Dr. Yancopoulos also currently serves as President of Regeneron.

After graduating as valedictorian at both Bronx High School of Science and Columbia University, Dr. Yancopoulos received his MD and PhD in Biochemistry and Molecular Biophysics from Columbia University. Later at Columbia, he served with legendary geneticist Dr. Fred Alt as his first post-doctorate student, working in molecular immunology. Dr. Yancopoulos was pursuing a career in academia until he met Dr. Schleifer in the late 1980s and saw the potential to make a major impact on medicine through biotechnology.

Regeneron is now a leading biopharma company with more than 6,500 employees and facilities in the United States, Ireland and the United Kingdom. With a robust research and development engine and an unwavering commitment to its science-driven approach, Regeneron has produced six FDA-approved drugs, including DUPIXENT® (dupilumab) for moderate-to-severe atopic dermatitis. Dr. Yancopoulos and his team have discovered important new medicines for patients with serious diseases, including cancer, vision-threatening eye diseases and rheumatoid arthritis, while also building a robust homegrown pipeline of investigational treatments.

Dr. Yancopoulos is a principal inventor of Regeneron's foundational technologies for target discovery and drug development, such as its proprietary VelociGene® and VelocImmune® platforms. Regeneron is committed to continual innovations in the drug discovery and development processthrough the Regeneron Genetics Center, a world-leading human genetics effort that has already sequenced exomes from over 300,000 people.

Dr. Yancopoulos is passionate about bringing his success in the sciences full circle, and is deeply committed to inspiring top talent to pursue scientific careers through STEM (Science, Technology, Engineering and Math) education programs. He plays an active role in Regeneron's STEM commitments, including the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science competition, formerly sponsored by Westinghouse and Intel.




Registration and Networking Café


Networking Lunch




State of the Industry


Panel: Masters of Industry


Entrepreneurial Company Showcase


Networking Break


Featured Speaker


Sponsor Showcase


Panel: Alopecia Areata


Sponsor Showcase


Entrepreneurial Company Showcase


Networking Break


Sponsor Showcase


Fireside Chat


Networking Reception



Conference Board of Directors

Frederick C. Beddingfield III is founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. He started Sienna in 2016 and took the company public in 2017. Prior to Sienna, Frederick served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in 2015. Frederick worked at Allergan for 10 years (2003-2013) where he led the development of global leading brands in medical dermatology and aesthetics including Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac. He has led multiple successful FDA advisor committees.

Since completing his training, Frederick has always maintained a clinical and teaching practice at UCLA where he is an Associate Clinical Professor. He is a board-certified dermatologist and emergency medicine physician and a fellowship trained dermatologic surgeon. Frederick completed his medical degree at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the board of directors of Cytrellis Biosystems, Inc. and on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder.

Albert Cha, MD, PhD. is a Managing Partner who invests in private and public biopharmaceutical and medical device companies. He currently serves on the boards of Ascendis Pharma A/S (NASDAQ: ASND), BioHaven Pharmaceuticals (NYSE: BHVN), KalVista Pharmaceuticals (NASDAQ: KALV), Menlo Therapeutics (NASDAQ: MNLO).

He was an investor in Aclaris Therapeutics (NASDAQ: ACRS), AirXpanders (ASX: AXP), ProNAi Therapeutics (NASDAQ: DNAI), Ceptaris Therapeutics (acquired by Actelion), Neomend (acquired by Bard), Vicept Therapeutics (acquired by Allergan), Bioform Medical (BFRM, acquired by Merz), Biodel (BIOD), and Aspreva Pharmaceuticals (NASDAQ: ASPV, acquired by Galenica). Albert was also involved in founding NextWave Pharmaceuticals (acquired by Pfizer) and Prestwick Pharmaceuticals (acquired by Biovail). Other investments include YM Biosciences (YMI), Dynavax Technologies (DVAX), Avanir Pharmaceuticals (AVNR), Acura Pharmaceuticals (ACUR), and AMAG Pharmaceuticals (AMAG). Albert is also a co-founder and board member of the annual Dermatology Summit and Dermatology Innovation Forum. Prior to joining Vivo, Albert worked at Oracle Corporation in pharmaceutical consulting and at the Palo Alto VA Hospital as a biomedical engineer.

John Doux, MD obtained a B.S. with distinction and an MD from Stanford University, where he was a Howard Hughes Medical Institute Fellow performing research in the laboratory of Dr. David Woodley. After an internship at Brigham and Women's Hospital in Boston, he returned to Stanford to complete his residency training in dermatology. He also completed an MBA at the Wharton School of Business where he was a Palmer Scholar. He is board certified in dermatology and maintains an active clinical practice. Since 2004 he has also served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare with $2B+ in assets under management.

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University. Dr. Ju is a co-founder of EdWiser, Inc. (now known as Zoomi, Inc.), is currently a member of the board of directors for Brickell Biotech, Inc., and serves on the Advisory Council for the Keller Center for Innovation Engineering Education at Princeton University.

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Dr. Neal Walker co-founded Aclaris Therapeutics and has served as President and Chief Executive Officer and a member of the board of directors since inception July 2012. He is a board certified dermatologist and serial entrepreneur with over 19 years of experience in the life science industry. He began his pharmaceutical industry career at Johnson & Johnson, Inc.

DDr. Walker co-founded NeXeption, LLC, a biopharmaceutical assets management company, in August 2012. Prior to Aclaris, he co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, Inc., a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Walker co-founded and led a number of life science companies, including Octagon Research Solutions, Inc., a software and services provider to biopharmaceutical companies (acquired by Accenture plc), Trigenesis Therapeutics, Inc., a specialty dermatology company, where he served as Chief Medical Officer (acquired by Dr. Reddy's Laboratories Inc.), and Cutix Inc., a commercial dermatology company. He also co-founded and serves on the Board of Directors of the Dermatology Summit, Dermatology Innovation Forum, and Advancing Innovation in Dermatology. Dr. Walker is a director of Alderya Therapeutics, Inc., a publicly held biotechnology company, as well as several private companies.

In 2016 Dr. Walker was awarded the Frank Baldino Bioscience CEO of the Year award, and also the Ernst & Young Entrepreneur of the Year Greater Philadelphia award. He is a Fellow of the American Academy of Dermatology, received his M.B.A. degree from The Wharton School, University of Pennsylvania, his Doctor of Osteopathic Medicine degree from the Philadelphia College of Osteopathic Medicine, and a B.A. degree in Biology from Lehigh University.



For Sponsorship Opportunities, please contact Rhonda Ware at rware@caravelgroupinc.com .


New! Conference App in 2019

This year the Dermatology Summit will be utilizing a conference app for the meeting material and networking appointments, available on both Apple and Android devices for all registered attendees.

This app will replace our conference networking software from recent years. Upon logging into the app, you will be able to network with other attendees and set up meetings in our 1:1 conference networking space.

Our app will launch in mid-November, and you will receive an email at that time with download instructions.



Event Details

Erin Conner, CMP
Caravel Group

Sponsorship Opportunities

Rhonda Ware
Caravel Group

Venue Details

Palace Hotel, San Francisco
2 New Montgomery Street,
San Francisco, CA 94105
(415) 512-1111
Hotel Website


Frequently Asked Questions

What is the agenda for the conference?

  • 9:30am – Registration and Networking
  • 11:00am – Networking Lunch
  • 12:00pm – Welcome
  • 12:10pm – State of the Industry
  • 12:30pm – Panel: Masters of Industry
  • 1:00pm – Entrepreneurial Company Showcase
  • 1:30pm – Networking Break
  • 2:10pm – Featured Speaker
  • 2:30pm – Sponsor Showcase
  • 2:50pm – Panel: Alopecia Areata
  • 3:20pm – Sponsor Showcase
  • 3:30pm – Entrepreneurial Company Showcase
  • 4:00pm – Networking Break
  • 4:45pm – Sponsor Showcase
  • 5:25pm – Fireside Chat
  • 6:00pm – Networking Reception

What is the cost of registration?

  • If registered by October 26, 2018 - $795
  • Registration after October 26, 2018 - $975

What is included in the registration fees?

Conference registration includes:

  • Networking Café
  • Networking Lunch
  • Networking Breaks
  • All Conference Sessions
  • Access to Conference App for Networking Opportunities
  • Evening Networking Cocktail Reception

How do I become a Sponsor?

If you are interested in a sponsorship opportunity, please contact Rhonda Ware at rware@caravelgroupinc.com, for the sponsorship overview and level pricing.


Our app will launch in mid-November, and you will receive an email at that time with download instructions to network with other conference attendees and set up 1:1 meetings in our dedicated networking space.

Where can I make hotel reservations?

There are several hotels within a short distance from the Palace Hotel, where the Dermatology Summit will take place. Please reference the list of hotels below for booking your own hotel room. The Dermatology Summit does not have contracted rates with these hotels.

Hotel Address Phone
Palace Hotel 2 New Montgomery Street 415-512-1111
Grand Hyatt San Francisco 345 Stockton Street 415-398-1234
Sir Francis Drake 450 Powell Street 415-392-7755
Westin St. Francis 335 Powell Street 800-937-8461
JW Marriott 510 Mason Street 415-771-8600
Stanford Court Hotel 905 California Street 415-989-3500
Prescott, A Kimpton Hotel 545 Post Street 415-563-0303
Hilton San Francisco Union Square 333 O'Farrell Street 415-771-1400
Hotel Monaco 501 Geary Street 415-292-0100
Ritz-Carlton 600 Stockton Street 415-296-7465
InterContinental Mark Hopkins 999 California Street 415-392-3434
The Clift Hotel 495 Geary Street 415-775-4700
Serrano Hotel 405 Taylor Street 415-885-2500
Marriott Union Square 480 Sutter Street 415-398-8900

What is the dress code?

Attire is business casual. Feel free to be comfortable in slacks, polo shirts, blazers, blouses and most importantly, comfortable shoes. We do recommend you dress in layers as temperatures in meeting rooms can vary.

I am a Sponsor. How do I redeem my contracted complimentary registration(s)?

After your sponsorship has been processed, you will receive an email with a unique code and instructions to register online. We encourage all complimentary and discounted registrations to be completed by December 7, 2018. If you have not yet received the email, please contact us at rware@caravelgroupinc.com.

Cancellation Policy

Requests for registration fee cancellations for the conference must be received on or before November 30, 2018 by 3pm Eastern Time. At the discretion of the conference organizers, a refund via the method of original payment, minus a $125 non-refundable administrative fee, will be issued. No refunds will be made if notice is received after 3pm Eastern Time on November 30, 2018. Written notice of your cancellation should be sent to econner@caravelgroupinc.com with a copy to info@advancing-derm.org.

Force Majeure

No damages or refunds shall be due for a failure of performance by the occurrence of any contingency beyond the reasonable control of AID or Caravel Group. These contingencies include, without limitation, threat of or actual war, terrorism, sabotage, insurrection, riot or other act of civil disobedience, act of public enemy, failure or delay in transportation, act of government or any agency affecting the terms of this Agreement, accident, fire, explosion, flood, severe weather, natural disaster, or other act of God, interruptions or failure of the Internet or third-party network connections, or acts beyond the reasonable control of the responsible parties making the Event impossible to hold.

Advancing Innovation in Dermatology, Inc. is a registered IRS 501(c)(3) organization designated as a public charity in the United States.